OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.
4475 Wayburne Drive
Unit 210
Burnaby, BC V5G 4X4
Canada
None
1500, 640 - 5th Avenue SW
Calgary, AB T2P 3G4
Canada
550 Burrard Street, Suite 2900
Vancouver, BC V6C 0A3
Canada
For pharmaceutical clinical trial candidates, Filament possesses the capabilities to manufacture in-house clinical drug candidates. In addition, Filament’s capabilities allow it to manufacture drug candidates for third parties wishing to pursue their own clinical development program. In these cases, Filament and the third parties will enter into intellectual property licensing agreements whereby Filament will potentially earn commercial milestones and royalty payments based upon future levels of commercialization met by the third party clinical development program. Filament’s first three botanical drug candidates are standardized, purified extracts of psilocybe cubensis fruiting bodies include: - PEX010 Psilocybin - oral delivery (1mg and 25mg) - PEX020 Psilocin - oral delivery (dose withheld) - PEX030 Psilocin - sublingual delivery (dose withheld) PEX010, PEX020 and PEX030 have successfully attained FDA Botanical Drug classification, a unique development pathway in comparison to isolated natural and synthetic compounds. As of March [31], 2022, Filament’s PEX010 drug candidate also obtained approval from Health Canada to be administered in clinical trials. Filament has also developed the following standardized drug candidates which are in preclinical stage: - AEX010 Ayahuasca - oral delivery (dose withheld) - AEX020 Monoamine Oxidase Inhibitor - oral delivery (dose withheld)
Fully operational mycology lab, production facility and head office located at 4475 Wayburne Drive, Unit 210, Burnaby, British Columbia, V5G 4X4. The Burnaby facility includes cultivation space and laboratory space used for the preparation of genetic material for the cultivation and manufacturing process. The processing space and equipment allows for the drying, extraction, purification and standardization of psychedelic substances. There is also a secure controlled substances environ that is only accessible to authorized individuals. The Burnaby facility measures 3,416 square feet and is a leased facility. Psilo’s GMP manufacturing, Dealer’s License and manufacturing capabilities enable Psilo to supply in-house human clinical trials as well as license technology to drug developers, researchers and other licensed parties.